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Abstract
Nucleoside	transporters	are	divided	into	two	families,	the	sodium-dependent,	concentrative	solute
carrier	family	28	(SLC28)	and	the	equilibrative,	solute	carrier	family	29	(SLC29).	The	endogenous
substrates	are	typically	nucleosides,	although	some	family	members	can	also	transport	nucleobases
and	organic	cations	[1].
Contents
This	is	a	citation	summary	for	SLC28	and	SLC29	families	of	nucleoside	transporters	in	the	Guide	to
Pharmacology	database	(GtoPdb).	It	exists	purely	as	an	adjunct	to	the	database	to	facilitate	the
recognition	of	citations	to	and	from	the	database	by	citation	analyzers.	Readers	will	almost	certainly
want	to	visit	the	relevant	sections	of	the	database	which	are	given	here	under	database	links.
GtoPdb	is	an	expert-driven	guide	to	pharmacological	targets	and	the	substances	that	act	on	them.
GtoPdb	is	a	reference	work	which	is	most	usefully	represented	as	an	on-line	database.	As	in	any
publication	this	work	should	be	appropriately	cited,	and	the	papers	it	cites	should	also	be	recognized.
This	document	provides	a	citation	for	the	relevant	parts	of	the	database,	and	also	provides	a
reference	list	for	the	research	cited	by	those	parts.	For	further	details	see	[5].
Please	note	that	the	database	version	for	the	citations	given	in	GtoPdb	are	to	the	most	recent
preceding	version	in	which	the	family	or	its	subfamilies	and	targets	were	substantially	changed.	The
links	below	are	to	the	current	version.	If	you	need	to	consult	the	cited	version,	rather	than	the	most
recent	version,	please	contact	the	GtoPdb	curators.
Database	links
SLC28	and	SLC29	families	of	nucleoside	transporters
https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=149
				SLC28	family
				https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=215
								Transporters
																CNT1(Sodium/nucleoside	cotransporter	1)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1114
																CNT2(Sodium/nucleoside	cotransporter	2)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1115
																CNT3(Solute	carrier	family	28	member	3)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1116
				SLC29	family
				https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=216
								Transporters
																ENT1(Equilibrative	nucleoside	transporter	1)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1117
																ENT2(Equilibrative	nucleoside	transporter	2)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1118
																ENT3(Equilibrative	nucleoside	transporter	3)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1119
																PMAT(Plasma	membrane	monoamine	transporter)
																https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1120
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